期刊文献+

干扰素-β治疗多发性硬化症疗效的Meta分析 被引量:3

The meta analysis of the effect of interferon-β in treatment of multiple sclerosis
下载PDF
导出
摘要 目的 研究干扰素-β与多发性硬化症疗效之间的关系。方法 检索纳入9篇(从2001~2010年)国际和国内有关干扰素治疗多发性硬化症的文献,应用随机效应模型和固定效应模型进行综合的定量分析,软件为Rev Man5.0。结果 干扰素-β治疗多发性硬化症复发的疗效的RR值为0.79,95%CI(0.66~0.94);发热症状的RR值为2.45,95%CI(1.57~3.80),P〈0.01;注射部位反应的RR值为5.11,95%CI(3.77~8.09),P〈0.01。结论 干扰素-β治疗多发性硬化症,可明显缓解发病情况,可以改善预后。 Objective To research the relationship between interferon-β and multiple sclerosis. Methods 9 papers (since 2001 to 2010) about international and domestic literature on interferon therapy for multiple sclerosis were retrieval included.Random effect model and fixed effect model were applied to analyze the comprehensive quantitative with RevMan5.0. Results The RR value of interferon- β in the treatment of multiple sclerosis was 0.79,95%CI was 0.66-0.94;Fever symptoms : RR=2.45,95%CI(1.57-3.80),P 〈0.01.Injecting site reaction : RR=5.11,95 % CI(3.77-8.09),P 〈 0.01. Conclusion Interferon- β therapy can obviously alleviate the incidence,can improve the prognosis
出处 《中国医药科学》 2015年第12期27-30,共4页 China Medicine And Pharmacy
关键词 干扰素-Β 治疗 多发性硬化症 疗效 META分析 Interferon- β Treatment Multiple sclerosis Curative effect Meta analysis
  • 相关文献

参考文献14

  • 1Frederik Barkhof, Mara Rocca, Gordon Francis, et al.Validation of Diagnostic Magnetic Resonance ImagingCriteria for Multiple Sclerosis and Response to Inteiferon.
  • 2Pakdaman H,Sahraian MA, Fallah A, et al.Effect ofearly interferon beta-la therapy on conversion to multiplesclerosis in Iranian patients with a first demyelinatingevenifj].Acta Neurol Scand, 2007,115: 429-431.
  • 3O Andersen, I Elovaara, M Fa, et al. Multicentre,randomised, double blind, placebo controlled, phase IIIstudy of weekly, low dose,subcutaneous interferon beta-la in secondary progressive multiple sclerosis[J].NeurolNeurosurgPsychiatry,2004, 75: 706-710.
  • 4Yann Mikaeloff, Guillaume Caridade, Marc Tardieu,et al.Effectiveness of early beta interferon on the firstattack after confirmed multiple sclerosis : A comparativecohort study[J].Official Journal of the European PaediatricNeurology Society,2008,12: 205-209.
  • 5Chris H, Polman,Ludwig Kappos,et al.Risk of developingMS and treatment effect of interferon beta-1 b[J].FreedmanNeurol,2008,255: 480-487.
  • 6X Montalban, J Sastre-Gaxriga, M Tintore, et al.A single一center, randomized, doubleblind, placebo-controlledstudy of interferon beta-lb on primary progressive andtransitional multiple sclerosis[J].Multiple Sclerosis, 2009,15 ( 10): 1195-1205.
  • 7Giancarlo Comi, Massimo Filippi,Frederik Barkhof,et al.Effect of early interferon treatment on conversion todefinite multiple sclerosis:a randomised study[J].Lancet,2001,357: 1576-1582.
  • 8L.Kappos, A.Traboulsee, C.Constantinescu,et al.Long-term subcutaneous interferon beta-la therapy in patients withrelapsing-remitting MS[J].Neurology, 2006,67 : 944-953.
  • 9Ludwig Kappos, Mark S Freedman, Chris H Polman,et al.Long-term effect of early treatment with interferonbeta-lb after a first clinical event suggestive of multiplesclerosis:5-year active treatment extension of the phase 3BENEFIT trial[J].Lancet Neurol,2009,8 : 987-997.
  • 10郭琳.干扰素-β治疗多发性硬化机制的研究进展[J].国外医学(免疫学分册),2003,26(6):329-332. 被引量:2

二级参考文献98

  • 1谢琰臣,张华,许贤豪.干扰素-β治疗多发性硬化[J].中国神经免疫学和神经病学杂志,2006,13(2):124-127. 被引量:10
  • 2龚林,卢少军,何国军.干扰素β治疗缓解复发型多发性硬化26例临床分析[J].中华神经医学杂志,2007,6(4):395-397. 被引量:4
  • 3Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committe on clinical trials of new agents in multiple sclerosis. Neurology, 1996,46(4):907-911.
  • 4Poser CM,Paty DW,Scheinberg L,et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol, 1983,13(3):227-231.
  • 5McDonald WI,Compston A,Edan G,et al. Recommended disgnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol, 2001,50:121-127.
  • 6Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983,33 (11): 1444-1452.
  • 7IFN-β Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis.Neruology, 1993, 43(41):655-661.
  • 8Lawrence D, Diane L, Richard A. Intramuscular interferon betala for disease progression in relapsing multiple sclerosis. Ann Neurol, 1996,39:285-294.
  • 9Becher B, Giaeomini N PS, Pelltier D, et al. [J].Ann Neurol, 1999,45(2) :247-250.
  • 10Gayo A,Mozo L, Suarez A, et al. [J]. Neurology, 1998,52(9): 1294-1300.

共引文献20

同被引文献41

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部